StageZero Life Sciences to Present at the New York City based Investor Summit on March 25th-26th.

written by Raj Shah | March 18, 2020

March 18, 2020 (Source) – StageZero Life Sciences (TSX:SZLS), is spearheading multiple cancer detection screening through their next generation test, Aristotle. StageZero Life Sciences will be presenting at this year's New York City based Investor Summit on March 25th-26th.

During the current climate of concern, The Spring Investor Summit will now take place virtually, featuring over 500 registered executives and investors.

Investors will still be able to view all the company presentations directly in the conference event platform on the event days. 1:1's will now be scheduled and conducted via phone lines with a dedicated PIN for each meeting.

You can view our company presentation via webcast here: https://www.webcaster4.com/Webcast/Page/2038/33701 on March 26th, 2020 at 09:40 a.m. EST.

About StageZero Life Sciences

StageZero Life Sciences is dedicated to the early detection of cancer and multiple disease states through whole blood.

Aristotle®, our next generation test, is a panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on our proven and proprietary Sentinel Principle Technology Platform which has been validated on 10,000 patients and used to develop the first liquid biopsy for Colorectal Cancer, with further validation currently underway. In addition to building a pipeline of products for early cancer detection, the Company operates a CAP accredited and CLIA certified reference laboratory based in Richmond, Virginia that offers the ColonSentry® test as well as licensed biomarker tests for lung, breast and prostate cancers. To learn more visit www.stagezerolifesciences.com.

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.